LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M plus ) advanced adenocarcinoma of the lung.
机构：[1]Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of MedicalSciences, Guangzhou, China研究所肺肿瘤科广东省肺癌研究所广东省人民医院[2]Department of Oncology, Shanghai Pulmonary Hospital, Shanghai, YangpuDistrict, China广东省人民医院[3]Department of Pulmonary Medicine, Xiangya Hospital, Central South University,Changsha, China[4]Department of Medical Oncology, Jiangsu Provincial Cancer Hospital, Nanjing,Jiangsu, China[5]Shanghai Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, ShanghaiJiaotong University, Shanghai, China[6]Department of Thoracic Surgery, Yunnan Tumor Hospital (TheThird Affiliated Hospital of Kunming Medical University), Kunming, Yunnan Province, China[7]CancerCenter, First Hospital of Jilin University, Changchun, China外科科室肿瘤科昆明医科大学附属第一医院[8]West China Hospital, Sichuan University,Chengdu, Sichuan, China四川大学华西医院[9]Lin Yi Tumor Hospital, Linyi, Shandong Province, China四川大学华西医院[10]Lung CancerCenter, Konkuk University Medical Center, Seoul, Korea[11]Boehringer Ingelheim Limited, Bracknell, UnitedKingdom[12]Boehringer Ingelheim Int'l Trading (Shanghai) Co., Ltd., Shanghai, China[13]Division ofRespiratory and Respiratory Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine,Prince of Songkla University, Songkhla, Thailand .
第一作者机构：[1]Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of MedicalSciences, Guangzhou, China
推荐引用方式(GB/T 7714)：
Wu Yi Long,Zhou Caicun,Hu Cheng-Ping,et al.LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M plus ) advanced adenocarcinoma of the lung.[J].JOURNAL OF CLINICAL ONCOLOGY.2013,31(15):
APA：
Wu, Yi Long,Zhou, Caicun,Hu, Cheng-Ping,Feng, Ji Feng,Lu, Shun...&Geater, Sarayut Lucien.(2013).LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M plus ) advanced adenocarcinoma of the lung..JOURNAL OF CLINICAL ONCOLOGY,31,(15)
MLA：
Wu, Yi Long,et al."LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M plus ) advanced adenocarcinoma of the lung.".JOURNAL OF CLINICAL ONCOLOGY 31..15(2013)
医学